Selective serotonin reuptake inhibitor-induced akathisia

Koliscak, Lindsey P.; Makela, Eugene H.

doi:10.1331/japha.2009.08083

Cited by 37 publications

(25 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Embora a quetiapina seja um bloqueador D2 de baixa afinidade e com muito baixa probabilidade de desencadear SEPs, há relatos de caso descrevendo situações em que indivíduos propensos a SEPs desenvolveram acatisia e outros SEPs ao serem expostos a esse antipsicótico atípico 8,9 . Em relação à suscetibilidade individual ao desenvolvimento de SEPs, pode-se afirmar que ainda não existem fatores predisponentes claramente estabelecidos, todavia já foi sugerido que portadores de transtornos do humor (mais especificamente depressão) e pacientes com deficiência de ferro têm risco aumentado para acatisia quando expostos a drogas antidopaminérgicas [10][11][12] .…”

Section: Discussionunclassified

Acatisia associada à bromoprida em um paciente deprimido usando fluvoxamina

Tomelin

Tonelli

2012

J. bras. psiquiatr.

View full text Add to dashboard Cite

resUMo contexto: A acatisia é definida clinicamente como uma sensação de agitação associada à necessidade de produção de movimentos, comumente deflagrada por bloqueadores dopaminérgicos, como os neurolépticos, podendo ocorrer também durante o tratamento com inibidores seletivos de recaptação de serotonina. É possível que drogas não psiquiátricas que bloqueiem receptores dopaminérgicos, como a bromoprida, possam causar sintomas extrapiramidais. objetivos: Descrever um desfecho desfavorável caracterizado por acatisia em um paciente depressivo previamente estabilizado com fluvoxamina, após usar bromoprida. Mé-todos: Descrição de um caso. resultados: Sr. J., paciente deprimido de 47 anos, estava estabilizado com fluvoxamina 200 mg por dia. Iniciou abruptamente com quadro de inquietação e necessidade de produzir movimentos voluntariamente a fim de aliviar esse desconforto. Há quatro dias havia iniciado o uso de bromoprida 30 mg por dia para tratamento de dispepsia. A suspensão da bromoprida promoveu alívio imediato dos sintomas. conclusão: A bromoprida, um bloqueador dopaminérgico, pode ter deflagrado acatisia em um paciente em uso de fluvoxamina. Os mecanismos farmacológicos relacionados a esse desfecho são discutidos. aBstract Background: Akathisia is clinically defined as a sensation of restlessness associated to a necessity to produce movements, commonly triggered by dopaminergic blockers, like neuroleptics, and it might occur during treatment with selective serotonine reuptake inhibitors. It is possible that non psychiatric drugs that block dopaminergic receptors, like bromopride, might cause patients to develop extrapyramidal symptoms. objectives: To describe an unfavorable outcome clinically characterized by akathisia in a depressed patient previously stabilized with fluvoxamine, after using bromopride. Methods: Case report. results: Mr J, 47 year-old depressed patient, had been stabilized with fluvoxamine 200 mg a day. He began abruptly with restlessness and an urgency to produce voluntary movements in order to alleviate such discomfort. Four days earlier he began using bromopride 30 mg a day to treat dyspepsia. Withdrawn of bromopride promoted an immediate relieve of the symptoms. conclusion: Bromopride, a dopaminergic blocker, might have triggered akathisia in a patient using fluvoxamine. The pharmacologic mechanisms regarding this outcome are discussed.

show abstract

Section: Discussionunclassified

Acatisia associada à bromoprida em um paciente deprimido usando fluvoxamina

Tomelin

Tonelli

2012

J. bras. psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Another idea is that akathisia constitutes a torment to such an extent that people in their desperation become (auto) aggressive. This side effect is typical for anti-psychotic medications, but is a regular feature of SSRIs [17][18][19], for instance, with fluoxetine showing an incidence rate of between 10% and 25%. Akathisia is also a symptom of a serotonerg syndrome featuring mental phenomena such as restricted awareness, (auto) aggression, neuromuscular phenomena and autonomous instability.…”

Section: Ssris and Violencementioning

confidence: 99%

Aspects of Causality: A Verdict Inquiry of a Case with SSRI Use

Brouwers¹,

Loonen²,

Nielen³

et al. 2014

JHS

View full text Add to dashboard Cite

Sometimes more than one expert advises the court. They use different notional frameworks in doing so, and may report different opinions about the case they examined. In this case, the authors discuss the relation between the use of a SSRI (serotonin reuptake inhibitor) and a fatal tragedy in a family where the mother was accused of killing her husband and daughter a few days after use of the SSRI. No fewer than seven experts were heard (four behavioral experts, one behavioral toxicologist, one pharmacist and one pharmacologist) at the ensuing trial, and various possible diagnoses were dealt with in the experts' reports and at trial. More attention must be paid to the mentally debilitating influence of SSRI medication on certain psychological functions shortly after its intake. Although a mono-causal relationship between that influence and the accused's intention is necessary to exculpate the accused from guilt, the authors believe that a singular connection is never happened in the case.

show abstract

“…SSRIs have occasionally been associated with akathisia [110]. Among SGAs, risperidone is particularly prone to cause extrapyramidal symptoms including akathisia, but aripiprazole may be prone to cause more akathisia than other SGAs [111].…”

Section: Pd Dis Decreasing Safetymentioning

confidence: 99%

Clinically relevant interactions between newer antidepressants and second-generation antipsychotics

Spina

León

2014

Expert Opinion on Drug Metabolism & Toxicology

100

View full text Add to dashboard Cite

More PK DI studies are needed to better establish dose correction factors after adding fluoxetine and paroxetine to aripiprazole, iloperidone and risperidone. Further PK DI studies and case reports are also needed to better establish the need for dose correction factors after adding i) fluoxetine to clozapine, lurasidone, quetiapine and olanzapine; ii) paroxetine to olanzapine; iii) fluvoxamine to asenapine, aripiprazole, iloperidone, lurasidone, olanzapine, quetiapine and risperidone; iv) high sertraline doses to aripiprazole, clozapine, iloperidone and risperidone: v) bupropion and duloxetine to aripiprazole, clozapine, iloperidone and risperidone; and vi) asenapine to paroxetine and venlafaxine. Possible beneficial PD DI effects occur after adding SGAs to newer antidepressants for treatment-resistant major depressive and obsessive-compulsive disorders. The lack of studies combining newer antidepressants and SGAs in psychotic depression is worrisome. PD DIs between newer antidepressants and SGAs may be more likely for mirtazapine and bupropion. Adding selective serotonin reuptake inhibitors and SGAs may increase QTc interval and may very rarely contribute to torsades de pointes.

show abstract

Selective serotonin reuptake inhibitor-induced akathisia

Cited by 37 publications

References 30 publications

Acatisia associada à bromoprida em um paciente deprimido usando fluvoxamina

Acatisia associada à bromoprida em um paciente deprimido usando fluvoxamina

Aspects of Causality: A Verdict Inquiry of a Case with SSRI Use

Clinically relevant interactions between newer antidepressants and second-generation antipsychotics

Contact Info

Product

Resources

About